SB 203580

SB 203580[1]
Names
Preferred IUPAC name
4-{4-(4-Fluorophenyl)-2-[4-(methanesulfinyl)phenyl]-1H-imidazol-5-yl}pyridine
Other names
RWJ-64809;
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.214.849 Edit this at Wikidata
EC Number
  • 688-252-3
UNII
  • InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25) ☒N
    Key: CDMGBJANTYXAIV-UHFFFAOYSA-N ☒N
  • InChI=1/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
    Key: CDMGBJANTYXAIV-UHFFFAOYAY
  • CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
Properties
C21H16FN3OS
Molar mass 377.43 g/mol
Appearance White to off-white solid
Solubility in DMSO 50 mg/mL
Hazards
GHS labelling:
GHS05: CorrosiveGHS07: Exclamation mark
Danger
H302, H318
P264, P270, P280, P301+P312, P305+P351+P338, P310, P330, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

SB 203580 is a specific inhibitor of p38α and p38β which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27. At low concentrations, it does not inhibit JNK activity. SB-203580 was recently assigned the INN Adezamapimod, and is currently in phase 2 clinical trials to prevent post-operative tissue adhesion.